Doha Declaration

Breakdown of WTO talks does not impact compulsory licensing pact

Despite the breakdown of negotiations at the Fifth World Trade Organization (WTO) Ministerial meeting in Cancun, Mexico, from 10-14 September 2003, a compulsory licensing agreement adopted by the WTO General Council prior to the Cancun meeting still stands1,2. The agreement will allow WTO members to import - under compulsory licences - drugs to treat various diseases that include but are not limited to HIV/AIDS, malaria and tuberculosis3-5. The new agreement addresses paragraph six of the 2001 Declaration on the TRIPS Agreement and Public Health , which called on the TRIPS Council to seek a solution to Article 31(f) of the TRIPS Agreement . Under Article 31(f), WTO members can authorise the production of patented products without permission from the `right holder' (i.e. compulsory licensing) in cases of public health crises, but the product must be `predominantly for the supply of the domestic market' in the country where the authorisation is issued. This obligation relating to the domestic market has been waived, allowing drugs manufactured under compulsory licence in one country to be exported to another.

The TRIPS Council will carry out an annual review of the new system to ensure its effective operation. It includes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Real-Time Release Of CRLs Is US FDA’s Goal, Agency Leaders Affirm

 

The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By 

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.

Base Benefit-Risk Decisions On Data, Not Opinion And Passion, CDER’s Tidmarsh Says

 
• By 

New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.